2025 Novel Drug Approvals

Read full text Summarise with VIRAT
Authors: Katherine Ghattas, Amanda Rawa
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The year 2025 marked another strong chapter in pharmaceutical innovation, with multiple novel therapies gaining approval from the U.S. Food and Drug Administration (FDA). These approvals reflect continued progress in addressing unmet medical needs across a wide range of disease states. This article reviews the FDA’s 2025 novel drug approvals, spotlighting a few therapeutic advancements and emerging trends. A comprehensive table of all approved agents is provided, along with a focused discussion of four particularly impactful therapies: donidalorsen (Dawnzera), taletrectinib (Ibtrozi), delgocitinib (Anzupgo), gepotidacin (Blujepa), etripamil (Cardamyst). Each of these agents represents a step forward in its respective field and shows the evolving landscape of modern therapeutics.

Fields of Study & Subjects

Pharmaceutical Economics and Policy Medical and Pharmaceutic Studies Pharmaceutical studies and practices

Publication details

Journal / source
Transformative Medicine
Volume
5
Issue
1
Pages
17–17
Publication date
30 March 2026
Language
EN